I think as really with any biomarker test, then careful development, but an extensive validation is key. And I think in the US, there has already been considerable training, testing and validation. But I think where we were excited about our work is that it was a very large external validation. And I think when you have well-powered, high-quality clinical trial outcomes with which to really test the model, then you maximize the quality of the validation work...
I think as really with any biomarker test, then careful development, but an extensive validation is key. And I think in the US, there has already been considerable training, testing and validation. But I think where we were excited about our work is that it was a very large external validation. And I think when you have well-powered, high-quality clinical trial outcomes with which to really test the model, then you maximize the quality of the validation work.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
